We currently represent several high quality biotech companies in multi-track licensing and M&A engagements, including:
A company with a novel proprietary first-in-class immunotherapy platform for solid and liquid tumors, with four clinical candidates, the most advanced in Ph II trials, available for licensing.
A company with a novel, proprietary, first-in-class humanized monoclonal antibody for the treatment of wet AMD, diabetic retinopathy and diabetic macular edema available for licensing.
A company with several targeted clinical-stage products based on their ceremide technology for orphan oncology indications, including PTCL, CTCL and neuroblastoma that are available for licensing.
A company with a novel treatment for short bowel syndrome, an orphan GI disorder with composition of matter, available for EU licensing.
Get our newsletter
Sign up for our email list
Download our presentation
Get a digital copy of our PDF presentation